Trials / Completed
CompletedNCT04076462
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With Acromegaly
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 72 (actual)
- Sponsor
- Camurus AB · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to assess the efficacy and safety of CAM2029 in patients with acromegaly. Patients will be randomized to either CAM2029 or placebo administered subcutaneously once monthly during 6 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CAM2029 (octreotide subcutaneous depot) | Octreotide subcutaneous depot for monthly injections in acromegaly patients |
| DRUG | Matching placebo | Matching placebo for CAM2029 |
Timeline
- Start date
- 2019-08-19
- Primary completion
- 2023-05-02
- Completion
- 2023-05-02
- First posted
- 2019-09-03
- Last updated
- 2024-04-25
Locations
63 sites across 10 countries: United States, Germany, Greece, Hungary, Italy, Poland, Russia, Spain, Turkey (Türkiye), United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04076462. Inclusion in this directory is not an endorsement.